Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Recent years have highlighted significant progress in understanding the underlying genetic
and epigenetic signatures of acute myeloid leukemia (AML). Most importantly, novel …

Purpose The aim of the current study was to determine whether the degree of mutation
clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia …

BACKGROUND Despite increasing data on the impact of the microbiome on cancer, the
dynamics and role of the microbiome in infection during therapy for acute myelogenous …

Acute myeloid leukemia--major progress over four decades and glimpses into the future. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …

Background Understanding longitudinal variability of the microbiome in ill patients is critical
to moving microbiome-based measurements and therapeutics into clinical practice …

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but
has yet to be critically evaluated in younger adults in the frontline with standard …

BACKGROUND Predicting outcomes for patients with acute myeloid leukemia (AML) on the
basis of pretreatment predictors has been the cornerstone of management. Posttreatment …

Historically, progress in leukemia research has been slow, but it has accelerated recently as
a result of understanding the pathophysiology of leukemias and implementing more effective …

Recent advances in therapeutics coupled with steady improvements in supportive care for
patients with acute myeloid leukemia (AML) have led to improved outcomes. Despite these …